V

VistaGen Therapeutics Inc
NASDAQ:VTGN

Watchlist Manager
VistaGen Therapeutics Inc
NASDAQ:VTGN
Watchlist
Price: 2.4999 USD 0%
Market Cap: 69.6m USD
Have any thoughts about
VistaGen Therapeutics Inc?
Write Note

VistaGen Therapeutics Inc
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

VistaGen Therapeutics Inc
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
V
VistaGen Therapeutics Inc
NASDAQ:VTGN
Cash from Investing Activities
-$13.3m
CAGR 3-Years
-227%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Investing Activities
-$19.7B
CAGR 3-Years
-121%
CAGR 5-Years
N/A
CAGR 10-Years
-20%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Investing Activities
-$4B
CAGR 3-Years
31%
CAGR 5-Years
6%
CAGR 10-Years
-13%
Amgen Inc
NASDAQ:AMGN
Cash from Investing Activities
-$27.7B
CAGR 3-Years
-304%
CAGR 5-Years
N/A
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Investing Activities
-$3.8B
CAGR 3-Years
N/A
CAGR 5-Years
-59%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Investing Activities
-$2.9B
CAGR 3-Years
8%
CAGR 5-Years
-7%
CAGR 10-Years
-17%
No Stocks Found

VistaGen Therapeutics Inc
Glance View

Market Cap
67.6m USD
Industry
Biotechnology

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California and currently employs 31 full-time employees. The company went IPO on 2010-10-18. The firm is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The firm's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).

VTGN Intrinsic Value
1.366 USD
Overvaluation 45%
Intrinsic Value
Price
V

See Also

What is VistaGen Therapeutics Inc's Cash from Investing Activities?
Cash from Investing Activities
-13.3m USD

Based on the financial report for Sep 30, 2024, VistaGen Therapeutics Inc's Cash from Investing Activities amounts to -13.3m USD.

What is VistaGen Therapeutics Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
-227%

Over the last year, the Cash from Investing Activities growth was -2 366%. The average annual Cash from Investing Activities growth rates for VistaGen Therapeutics Inc have been -227% over the past three years .

Back to Top